Leerink Partnrs Has Pessimistic View of VRDN Q2 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for Viridian Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($1.08) per share for the quarter, down from their prior forecast of ($0.94). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics' Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($4.56) EPS, FY2026 earnings at ($3.59) EPS, FY2027 earnings at ($2.08) EPS, FY2028 earnings at $0.82 EPS and FY2029 earnings at $2.48 EPS.

Several other research analysts have also recently commented on VRDN. Needham & Company LLC reduced their target price on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. The Goldman Sachs Group lowered their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada reduced their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, JMP Securities dropped their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $36.70.

Viridian Therapeutics Stock Performance

VRDN stock traded up $0.73 during midday trading on Friday, hitting $13.12. 942,955 shares of the company traded hands, compared to its average volume of 1,196,147. Viridian Therapeutics has a twelve month low of $9.90 and a twelve month high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -3.04 and a beta of 0.57. The business has a 50 day simple moving average of $13.71 and a 200-day simple moving average of $17.44.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. The company's quarterly revenue was up .0% compared to the same quarter last year.

Institutional Trading of Viridian Therapeutics

Hedge funds have recently made changes to their positions in the company. Knott David M Jr increased its holdings in Viridian Therapeutics by 20.0% in the first quarter. Knott David M Jr now owns 30,000 shares of the company's stock worth $404,000 after purchasing an additional 5,000 shares in the last quarter. Nuveen LLC purchased a new position in shares of Viridian Therapeutics during the 1st quarter valued at $3,352,000. Invesco Ltd. lifted its position in shares of Viridian Therapeutics by 44.3% during the 1st quarter. Invesco Ltd. now owns 47,771 shares of the company's stock valued at $644,000 after buying an additional 14,672 shares during the last quarter. DCF Advisers LLC raised its stake in shares of Viridian Therapeutics by 108.5% during the 1st quarter. DCF Advisers LLC now owns 62,029 shares of the company's stock valued at $836,000 after purchasing an additional 32,279 shares during the period. Finally, J. Safra Sarasin Holding AG increased its stake in Viridian Therapeutics by 99.4% in the 1st quarter. J. Safra Sarasin Holding AG now owns 72,672 shares of the company's stock worth $980,000 after acquiring an additional 36,219 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.